The disclosure on shifting of registered office of the Company within the local limits of the city of Chennai is submitted.
DRAGARWQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr. Agarwals Eye Hospital's board, at its February 3, 2026 meeting, approved unaudited results for Q3 and nine months ended December 31, 2025. Revenue from operations rose to ₹116.22 crore in Q3 FY26 from ₹95.11 crore in Q3 FY25, a growth of about 22%. Net profit after tax jumped to ₹17.28 crore from ₹10.40 crore, up roughly 66% year-on-year. For the nine-month period, revenue grew to ₹350.86 crore (from ₹297.32 crore) and net profit rose to ₹53.86 crore (from ₹38.66 crore). The board also approved shifting the registered office within Chennai, from Buhari Towers on Moores Road to a new 6th floor address on 1st Main Road, Austin Nagar, Alwarpet, effective February 5, 2026. The auditor's review was conducted by S.R. Batliboi & Associates LLP, noting the previous period comparatives were reviewed by a predecessor auditor, indicating an auditor change. The company also disclosed a pending amalgamation scheme with its holding company, Dr. Agarwal's Health Care Limited, and a completed ₹70 crore preferential share allotment to the same holding company at ₹5,270 per share.
Strong Q3 and 9M earnings beat — revenue and profit growth well ahead of the prior year — should be viewed positively by shareholders. The registered office shift and pending amalgamation with the holding company are administrative and structural in nature with no immediate financial impact. The change in statutory auditor and large related-party preferential allotment are worth tracking closely.